Takao Morinaga

Chiba Cancer Center — Japan

Medicine · Health Sciences

11h-index585citations112works3.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(72), Immune Cell Function and Interaction(53), CAR-T cell therapy research(37), Immunotherapy and Immune Responses(32), Cancer Research and Treatments(11)

Publications112 total

Strategic selection of MDM2 inhibitors enhances the efficacy of FAK inhibition in mesothelioma based on TP53 genotype
PLoS ONE·2026Open Access
Pan-cancer analysis of RNA expression signatures associated with cancer tissue architecture
British Journal of Cancer·2025Open Access
Data from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Tables from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S9 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S7 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S10 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S8 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S4 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S2 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S6 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S1 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure 3 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S5 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Downregulation of <scp>sST2</scp> , a decoy receptor for interleukin‐33, enhances subcutaneous tumor growth in murine pancreatic cancer cells
FEBS Open Bio·2025· 1 citedOpen Access
PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
Cancer Immunology Research·2025· 2 cited
Author Correction: Immune evasion through mitochondrial transfer in the tumour microenvironment
Nature·2025· 2 citedOpen Access
Author response for "Downregulation of &lt;scp&gt;sST2&lt;/scp&gt;, a decoy receptor for interleukin‐33, enhances subcutaneous tumor growth in murine pancreatic cancer cells"
2025
Abstract 6172: PI3K/Akt signaling pathway regulates CD155 expression involved in resistance to cancer immunotherapy
Cancer Research·2025
Publisher Correction: Immune evasion through mitochondrial transfer in the tumour microenvironment
Nature·2025· 5 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Masahito Kawazu(27), Yosuke Togashi(27), Takashi Inozume(25), Shusuke Kawashima(24), Joji Nagasaki(22), Takehiro Ohnuma(22), Tatsuyoshi Kawamura(22), Youki Ueda(21), Akiko Honobe‐Tabuchi(21), Yoshiyasu Umeda(21), Yukiko Kiniwa(21), Hiroyoshi Nishikawa(19), Yu Kawahara(18), Yasuhiro Nakamura(18), Katsushige Kawase(16), Toyoyuki Hanazawa(16), Hiroyuki Mano(13), Jason Lin(12), Eiki Ichihara(12), Masatoshi Tagawa(12)